AstraZeneca Plc and Bristol Myers Squibb have reportedly held preliminary discussions about a potential merger that could create one of the world’s largest pharmaceutical companies, with a combined market value approaching $400 billion. The combination would unite two global leaders in oncology, creating a pharmaceutical powerhouse with extensive cancer, cardiovascular, and rare disease portfolios. In 2025, oncology products generated approximately $25 billion in revenue, nearly half of AstraZeneca’s total sales. Bristol Myers Squibb is also heavily focused on cancer therapies, with oncology accounting for more than 40% of its revenue during the first half of 2026. A potential AstraZeneca-Bristol Myers merger would also carry strategic implications, as a UK-based company would effectively acquire one of America’s leading pharmaceutical firms.